Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma

Trial Profile

Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; MK 4166 (Primary) ; Nivolumab (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Dec 2018 Planned End Date changed from 1 Nov 2023 to 1 Jan 2024.
    • 11 Dec 2018 Planned primary completion date changed from 1 Nov 2021 to 1 Jan 2022.
    • 11 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top